Antibody therapeutics provide cell-specific recognition customized for a patient. They offer the ability to treat cancers and autoimmune diseases with fewer side effects than traditional treatments such as chemotherapy. As the scientific understanding of traditional monoclonal antibody therapeutics has advanced, researchers have moved into engineering proteins to create next-generation antibody modalities.
This e-book explores solutions for common purification, analysis, and quality evaluation challenges when manufacturing modern antibody-derived therapies. Tools such as affinity chromatography, quantitative polymerase chain reaction (qPCR), and single-domain antibodies provide effective and flexible solutions for improving the efficiency and reliability of antibody biomanufacturing practices.